Clinical Trials Logo

Clinical Trial Summary

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and higher mechanical index, the role of Sonazoid in the early diagnosis of Endometrial carcinoma was explored.


Clinical Trial Description

Sonazoid is a second generation ultrasound contrast agent, which is composed of microbubbles containing chemically stable and insoluble Perfluorobutane (PFB) gas and a hard shell of phosphatidylserine sodium (2-3 μ m in diameter) wrapped in the outer layer. These microbubbles can generate stable nonlinear oscillations in a low-power acoustic field and generate echoes at the second harmonic frequency of the transmitted pulse for enhanced contrast harmonic imaging. Because Sonazoid has the advantages of ultra long time development and good stability, Sonazoid has significant clinical advantages in the diagnosis of not focal liver lesions(FLLs) but breast tumor and other organ. However, there is no study based on contrast enhanced ultrasound(CEUS) using Sonazoid in early detection of Endometrial carcinoma. Therefore, based on the advantages of the new ultrasound contrast agent, using qualitative analysis and quantitative analysis method to collect large samples, compared with diagnosis results of standard reference, which has important clinical significance for early diagnosis, early detection and improving the accuracy of diagnosis of Endometrial carcinoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04961775
Study type Observational
Source Chinese PLA General Hospital
Contact Jing Zhang, Doctor
Phone 13910535695
Email zjbch@vip.sina.com
Status Recruiting
Phase
Start date October 1, 2020
Completion date August 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05647109 - Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
Recruiting NCT04491643 - Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma Phase 2
Recruiting NCT05675787 - Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia Phase 2